CytoMed Therapeutics Ltd. has been granted a patent by the China National Intellectual Property Administration (CNIPA) for its proprietary gamma delta T cell technology and the associated chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570153-en) on November 06, 2025, and is solely responsible for the information contained therein.